Prometic Life Sciences Inc.'s president and CEO, Pierre Laurin, told BioWorld Today that "anything can happen here," as the company pursues work with the oral antifibrotic PBI-4050, but for now the FDA has agreed on the design of the first of the Laval, Quebec-based firm's pair of planned phase II/III trials in idiopathic pulmonary fibrosis (IPF).